Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at 2008 BIO Investor Forum

BUFFALO, NY--(Marketwire - October 21, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the 2008 BIO Investor Forum in San Francisco, October 29-31,...
October 15, 2008 09:21 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Doses First Healthy Volunteer in Initial Safety Study for Protectan CBLB502

BUFFALO, NY--(Marketwire - October 15, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for...
September 29, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Maxim Group Growth Conference

BUFFALO, NY--(Marketwire - September 29, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Maxim Group Growth Conference in New York City...
September 23, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present Protectan CBLB502 at 2008 BARDA Day

BUFFALO, NY--(Marketwire - September 23, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it will present Protectan CBLB502 at the 2008 Biomedical Advanced Research and Development...
September 16, 2008 11:30 ET | Source: Cleveland BioLabs, Inc.

Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) Awards Cleveland BioLabs Contract to Develop Protectan CBLB502

BUFFALO, NY--(Marketwire - September 16, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of...
September 12, 2008 08:44 ET | Source: Cleveland BioLabs, Inc.

National Institute of Allergy and Infectious Diseases Awards Cleveland BioLabs Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage

BUFFALO, NY--(Marketwire - September 12, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has been awarded a $774,183 grant from the National Institute of Allergy and Infectious...
August 13, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs and Cleveland Clinic Demonstrate Accelerated Recovery of Limb Function With Protectan CBLB502 in Tourniquet Injury Model

BUFFALO, NY--(Marketwire - August 13, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and founding partner Cleveland Clinic reported today that CBLI's lead product, Protectan CBLB502, currently being...
August 07, 2008 08:18 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Receives Notice of Allowance From FDA to Commence Clinical Testing With Protectan CBLB502

BUFFALO, NY--(Marketwire - August 7, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today the allowance from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in...
July 08, 2008 08:30 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Granted First Patent for Protectan CBLB502

BUFFALO, NY--(Marketwire - July 8, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that its first patent for Protectan CBLB502 was granted by the Eurasian Patent Organization (EAPO),...
May 29, 2008 14:55 ET | Source: Cleveland BioLabs, Inc.

Cleveland BioLabs Featured in Note From CEO of The Robins Group, LLC

BUFFALO, NY--(Marketwire - May 29, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it was highlighted in a "Sales Note" issued by Marc Robins, CFA and Chief Executive Officer of...